Bessemer Group
EPIX

Bessemer Group’s ESSA Pharma EPIX Stock Holding History

Bessemer Group’s Portfolio EPIX Stock Details EPIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-6,852
Closed -$20K – 2281
2023
Q1 		$20K Hold
6,852
– – ﹤0.01% 1376
2022
Q4 		$17K Hold
6,852
– – ﹤0.01% 1338
2022
Q3 		$12K Hold
6,852
– – ﹤0.01% 1501
2022
Q2 		$22K Hold
6,852
– – ﹤0.01% 1241
2022
Q1 		$42K Buy
+6,852
New +$60.2K ﹤0.01% 1113

Other funds holding EPIX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return

Bessemer Group's EPIX Position: Q2 2023 in Review

Bessemer Group sold out of ESSA Pharma (EPIX) in Q2 2023, closing a stake of 6,852 shares — an estimated $20K sold.

Bessemer Group first reported a position in EPIX in Q1 2022 and held it in 5 quarters. The position peaked at $42K in Q1 2022. 39 funds tracked by Wall St. Rank hold EPIX as of Q2 2023.

  • Bessemer Group reported no remaining ESSA Pharma position as of Q2 2023 after selling out during the quarter.
  • Bessemer Group sold 6,852 ESSA Pharma shares in Q2 2023, an estimated $20K.
  • Bessemer Group first reported a position in ESSA Pharma in Q1 2022 and held it in 5 quarters.
  • Bessemer Group's ESSA Pharma position peaked at $42K in Q1 2022.
  • 39 funds tracked by Wall St. Rank held ESSA Pharma as of Q2 2023.

Based on Bessemer Group's 13F filing for Q2 2023, filed 10 Aug 2023.